Umbilical vein injection of misoprostol versus normal saline for the treatment of retained placenta: intrapartum placebo-controlled trial

BMC Pregnancy and Childbirth

Shahla K Alalaf²  Sheelan S Rajab¹ 

[1] Department of Obstetrics and Gynaecology, Shaheed Dr.Khalid General Hospital, Erbil City, Iraq;Department of Obstetrics and Gynaecology, College of Medicine, Hawler Medical University, Erbil City, Iraq

关键词: Active management of third stage of labour;    Retained placenta;    Intraumbilical misoprostol;   

Others  :  1131725
DOI  :  10.1186/1471-2393-14-37

 received in 2013-04-16, accepted in 2014-01-16,  发布年份 2014

【 摘 要 】

Background

The third stage of labour may be complicated by retained placenta, which should be managed promptly because it may cause severe bleeding and infection, with a potentially fatal outcome. This study evaluated the effectiveness of umbilical vein injection of misoprostol for the treatment of retained placenta in a hospital setting.

Methods

This hospital-based placebo-controlled trial was conducted at the Maternity Teaching Hospital, Erbil City, Kurdistan region, Northern Iraq from April 2011 to February 2012. The inclusion criteria were: gestational age of at least 28 weeks, vaginal delivery, and failure of the placenta to separate within 30 minutes after delivery of the infant despite active management of the third stage of labour. Forty-six women with retained placentas were eligible for inclusion. After informed consent was obtained, the women were alternately allocated to receive umbilical vein injection of either 800 mcg misoprostol dissolved in 20 mL of normal saline (misoprostol group) or 20 mL of normal saline only (saline group). The women were blinded to the group allocation, but the investigator who administered the injection was not. The trial was registered by the Research Ethics Committee of Hawler Medical University.

Results

After umbilical vein injection, delivery of the placenta occurred in 91.3% of women in the misoprostol group and 69.5% of women in the saline group, which was not a significant difference between the two groups. The median vaginal blood loss from the time of injection until delivery of the placenta was significantly less in the misoprostol group (100 mL) than in the saline group (210 mL) (p value < 0.001).

Conclusion

Umbilical vein injection of misoprostol is an effective treatment for retained placenta, and reduces the volume of vaginal blood loss with few adverse effects.

Clinical Trial Registration

Current Controlled Trial HMU: N252.1.2011

【 授权许可】

   
2014 Rajab and Alalaf; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hidar S, Jennane TM, Bouguizane S, Lassoued L, Bibi M, Khairi H: The effect of placental removal method at cesarean delivery on perioperative hemorrhage: a randomized clinical trial ISRCTN 49779257. Eur J Obstet Gynecol Reprod Biol 2004, 117:179-182.
• [2]National Collaborating Centre for Women’s and Children’s Health (NCCWCH): Intrapartum Care. Care of healthy women and their babies during childbirth. London: RCOG Press; 2007.
• [3]Ely JW, Rijhsinghani A, Bowdler NC, Dawson JD: The association between manual removal of placenta and postpartum endometritis following vaginal delivery. Obstet Gynecol 1995, 86:1002-1006.
• [4]Deyer TW, Ashton-Miller JA, Van Baren PM, Pearlman MD: Myometrial contractile strain at uteroplacental separation during parturition. Am J Obstet Gynecol 2000, 183:156-159.
• [5]Carroli G, Belizan JM, Grant A, Gonzalez L, Campodonico L, Bergel E: Intraumbilical vein injection and retained placenta: evidence from a collaborative large randomized controlled trial. Br J Obstet Gynaecol 1998, 105:179-185.
• [6]Purwar MB: Practical recommendations for umbilical vein injection formanagement of retained placenta. In The WHO Reproductive Health Library, Volume 4. Edited by Gulmezoglu AM, Villar J. Geneva: World Health Organization; 2001.
• [7]Nardin JM, Weeks A, Carroli G: Umbilical vein injection for management of retained placenta. The Cochrane Library, 2012, Issue 2. John Wiley & Sons, Ltd: The Cochrane Collaboration; 2012.
• [8]Weeks A, Alia G, Vernon G, Namayanja A, Gosakan R, Majeed T, Hart A, Jafri H, Nardin J, Carroli G, Fairlie F, Raashid Y, Mirembe F, Alfirevic Z: Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial. Lancet 2010, 375:141-147.
• [9]Pipingas A, Hofmeyr GJ, Sesel KR: Umbilical vessel oxytocin administration for retained placenta: in-vitro study of various infusion techniques. Am J Obstet Gynecol 1993, 168:793-795.
• [10]Rogers MS, Yuen PM, Wong S: Avoiding manual removal of placenta:evaluation of intra-umbilical injection of uterotonics using the Pipingas technique for management of adherent placenta. Acta Obestet Gynecol Scand 2007, 86:48-54.
• [11]Hoj L, Cardoso P, Nielsen BB, Hvidman L, Neelsen J, Aaby P: Effect of sublingual misoprostol on severe postpartum haemorrhage in aprimary health centerin Guiea-Bissau:randomised double blind clinical trial. BMJ 2005, 331:723.
• [12]Challis JRG, Lye SJ: Physiology and endocrinology of term and preterm labor. In Obstetrics: Normal and Problem Pregnancies. Edited by Gabbe SG, Niebyl JR, Simpson JL. New York: Churchill Livingstone; 2002. Fourth edition
• [13]Harara R, Hanafy S, Zidan MS, Alberry M: Intraumbilical injection of three different uterotonics in the management of retained placenta. J Obstet Gynaecol Res 2011, 37:1203-1207.
• [14]Bider D, Dulitzky M, Goldenberg M, Lipitz S, Mashiach S: Intraumbilical vein injection of prostaglandin in retained placenta. Eur J Obstet Gynecol Reprod Biol 1996, 64:59-61.